Skip to main content

JOIN THE LIST, GET THE IPO TRADING GUIDE

Author: hammondish

IPO Trading Review for the Week of October 31, 2022 – November 4, 2022

IPO Trading Review for the Week of October 31, 2022 – November 4, 2022

November 6th, 2022

The low-float IPOs keep getting rescheduled, and last week’s Fed announcements tanking the market didn’t help their causes at all. However, it does look like we’ll have a couple of IPOs get to the starting line this week, and Chinese variants continue to update their F-1 filing. A couple of uplistings are on-watch for potential Stealth plays as well, and early pre-market PR drops have produced some substantial wins: so there’s plenty of opportunities out there in IPO land despite the dearth of new issues.

Another opportunity that appears to be in-play for Monday’s trading session, is the 3 day bounce off negative reactions to Fed announcements: particularly in recent mainstream IPOs in the growth/tech space. Two that I have consistantly watched and played again-and-again are Unity (U) and SentinelOne (S) – both are at all-time-lows off the last round of fed-induced FUD, and each has rebounded hard off the bottoms of previous dips. It’s rather well accepted that recent IPOs tend to drop hardest and fastest in a broad market decline, and rebound/rally fastest on the way back up.

With no IPOs to review from last week, I’ll just jump into the recent IPOs that ran on pre-market PR drops.

+++
Ok, Let’s take a look at what happened last week in IPO Land:

Recent IPO Runners:

We often see recent IPOs, especially the low-float variety, make monster runs after consolidation following their IPO. Often, these moves coincide with their 90 and 180 day lockup expiration periods (“LPX Plays”): this is a play we actively track and discuss in the weekly preview newsletter.

Forza X1 (FRZA)
Catalyst:
Water testing their boat and boat reservations
Type:
IPO
IPO Date: August 12, 2022
IPO Price: $5.00
LPX Date:
November 12, 2022 (based on 90 day lockup)
LPX Period: 90 days
Historical LPX Notes: This one popped on the IPO debut as it went live amidst the post-HKD eurphoria.
Outstanding Shares: 10.45M
Close day before vol:
$1.69
High of the Day on vol: $2.76
Recap: This one was on watch going into LPX, and the back-to-back PR drops made it an easy spot on the Day 2 pump. I was able to patiently wait for a pullback off the initial move up to $2.31 to take a position on the drop just below $2.00 and rode it up to my target of $2.50 (exiting at $2.55 with a trailing stop).
Looking Ahead: To view this content, please subscribe to a Premium Membership.

+++

Virax Biolabs (VRAX)
Catalyst: New product announcement
Type: IPO
IPO Date: July 21, 2022
IPO Price: $5.00
LPX Date: October 21, 2022
LPX Period: 90 days
Historical LPX Notes: VRAX was a bit of a Boustead Specail when it debuted at $20.00 and bounced around for the first two weeks of trading on relatively low volume. It jumped again at the end of August with a spike on November 1, 2022 and has since declined from there until last weeks pump.
Free Float: 4.35M (read below regarding last Friday’s offering)
Shares Out: 11.37M
Close day before vol: $1.68
High of the Day on vol: $2.66.
Looking Ahead: To view this content, please subscribe to a Premium Membership.

+++

Huadi International (HUDI)
Catalyst: Announced plan to enter new energy industry, with discussions announced with Sichuan Local Government
Type: IPO
IPO Date: January 22, 2021
IPO Price: $5.00
LPX Date: NA
LPX Period: NA
Historical LPX Notes: This wasn’t so much of an LPX play, as far as I’m aware of, as what appears to be a Stealth IPO-type squeeze. HUDI has been volatile ever since it initiated a choppy climb from the $3 range up to $35 in October 2021. Since then, it has bounced around rather unpredictably
Free Float: 3.24M
Shares Out: 13.24M
Close day before vol: $30.84
High of the Day on vol: $192.88.
Looking Ahead: To view this content, please subscribe to a Premium Membership.

+++

Recent Posts

Continue reading

IPO Trading Review for the Week of October 17, 2022 – October 21, 2022

IPO Trading Review for the Week of October 17, 2022 – October 21, 2022

October 23, 2022

The mainstream underwriters finally were able to out-maneuver their lesser-esteemed counterparts last week, as a mainstream IPO managed to do what none of the low-float candidates on the calendar at the start of the week could manage, and debuted on a major exchange.

The results weren’t all that encouraging for future mainstream deals, and we’ve already seen Instacart scared off from attempting to list this year. Mainstream IPOs desperate enough to proceed in this market may be worth consideration based on the theory that retail traders would conceivably be getting an opportunity to buy in at a ‘more reasonable’ price than that which we were presented with in most IPOs over the past few years.

On the low-float IPO front, we’re still not seeing much enthusiasm in the retail sector to get any of the slated deals into the starting blocks, let alone provide a high-conviction setup for a significant allocation request or a debut trade. That may change if we can get a debut runner, but with all the scrutiny coming down from NASDAQ on these deals, it’s hard to imagine the underwriters being able to conjure their forces of market sorcery under such watchful eyes.

+++

Ok, Let’s take a look at what happened last week in IPO Land:

Prime Medicine (PRME) – October 20, 2022 | 10.3M Shares
IPO Price: $17.00
Debut Price: $18.97
Day 1 High: $19.00
Day 1 Low: $15.00
High Since Debut: $19.00
Low Since Debut: $14.40

Day 1 Action: PRME managed to drum up sufficient ‘smart money’ demand to not only debut at mid-range, but upsized the deal from 8.9M shares to 10.3M shares by the time they went live in a relatively weak market. Beyond that, the stock opened at a premium of $18.97 and for a minute, it looked like it might hold the debut price and muster a rally… a minute later, reality set in, and the stock started what would become a steady decline down to a bottom at $15.27 before it delivered any kind of reversal: a rally back up to $16.50 that ran out of steam long before the end of regular market hours, and before close it made new lows at $15.10 before a slight rally into the close at $15.37.

Day 2 Action: Day 2 pre-market spikes as high as $17.00 might look nice on the chart, but the volume was so low as to be meaningless (just 23 shares traded on that candle), but Day 2 did get started on the right foot, opening at $15.48 before dumping down to $14.94 within the first 15 minutes of trading. But from there it managed to climb back to as high as $16.24 on the day, closing the week $15.76.

Looking Ahead: To view this content, please subscribe to a Premium Membership. +++

Recent IPO Runners:

I was on holiday last week, and will return to my desk Thursday this week, so I didn’t have my eyes on the daily movers, but it doesn’t seem like we had much action in IPO land last week. Hopefully with the 90-day LPX of the post-HKD slate approaching, we see some action in that sector.

+++

Recent Posts

Continue reading

IPO Warriors IPO and LPX Preview for October 17 – October 21, 2022

IPO Warriors IPO and LPX Preview for October 17 – October 21, 2022

October 18, 2022

I guess it doesn’t take much to get the market back in the mood for IPOs – after worse-than-expected CPI data last Friday, the market tanked as expected. But over the weekend, it seems that traders decided it either wasn’t that bad, it was already priced in, perhaps we’d at least gotten closer to the bottom, or perhaps just “screw it – buy more stocks”… and Monday saw a strong rebound rally that carried into Tuesday. And so now we MIGHT have conditions conducive to a few IPOs!

We even have a mainstream IPO coming onto the calendar this week, albeit a biotech, and the low-float IPOs are all faces that we’ve become perhaps a bit too familiar with due to their persistent attempts to debut despite repeated failures to fill their order books. I’m not sure that a less tepid market makes these offerings any more appealing, and I don’t have any reason to believe that all of a sudden there will be high demand for these debuts from day traders. With the NASDAQ scrutinizing every issue that comes to market, it will be surprising if any of these are able to pull off the kind of shenanigans that have ensured a significant pop off the debut in some of these setups, and I don’t see anything resembling the kind of hype that has sent these setups on substantial post-debut rallies in recent years (and nothing even close to what we saw after HKD re-configured day traders’ perceptions of what was possible).

I’ll be mostly watching this week’s debuts from the sidelines – partially due to a planned family vacation, but also simply because we haven’t seen an IPO deliver a strong debut trade since NASDAQ reigned in the IPO train.

+++

This Week’s IPOs:

  • Alopexx (ALPX) – October 20, 2022 | 3M Shares

  • Prime Medicine (PRME) – October 20, 2022 | 8.9M Shares

  • Beamr Imaging (BMR) – October 21, 2022 | 3M Shares

  • Intensity Therapeutics (INTS) – October 21, 2022 | 2.22M Shares

+++

Ok, Let’s jump in:

To view this content, please subscribe to a Premium Membership.

Lockup Period Expiration (LPX) Watch:

Most IPOs are subject to either 90 or 180 day lockup periods before insiders and shareholders who owned shares of a company prior to the IPO can sell their positions. Typically, the dilutionary effect of this event will cause a stock price to drop, as supply increases without any fundamental changes in the value of the underlying company. Many investors will wait for LPX before starting a long term position in a company.
Conversely, with low-float IPOs, we often see press releases and other announcements dropped going into, or slightly following LPX, presumably as insiders attempt to drive up the share price before they are able to exercise their warrants and sell their shares.

+++

To view this content, please subscribe to a Premium Membership.

+++

Recent Posts

Continue reading

IPO Warriors IPO and LPX Preview for October 3 – October 7, 2022

IPO Warriors IPO and LPX Preview for October 3 – October 7, 2022

October 6, 2022

Well, after LASE basically crapped the bed in it’s rather well-structured IPO last week, it seems that we have no IPOs on the calendar this week. Though we’d hoped for ALPX to debut (I mean, perhaps “hope” isn’t really applicable since there was nothing particularly enticing about that offering), it appears to have been pushed due to lack of interest from investors.

So… for the time being, I’m looking at some Lockup Expiration setups for Chinese Stealth deals that were done about 5 months ago with LPX dates coming at the end of the month, and scalping some day trades here and there on early pre-market headlines.

These setups and more are continuously discussed everyday in our active trading community in the IPOWarriors Discord Channel
Live IPO trading and commentary on upcoming IPOs will be reserved for Premium Members within the #premium-members-room, but currently, there is a plethora of winning call-outs being made on a daily basis by regular contributors to the group (which includes some highly followed and well-known Twitter accounts with expertise in chart reading, SPACs, options trading, and more).

+++

This Week’s IPOs:

  • Nothin’

+++

Lockup Period Expiration (LPX) Watch:

Most IPOs are subject to either 90 or 180 day lockup periods before insiders and shareholders who owned shares of a company prior to the IPO can sell their positions. Typically, the dilutionary effect of this event will cause a stock price to drop, as supply increases without any fundamental changes in the value of the underlying company. Many investors will wait for LPX before starting a long term position in a company.
Conversely, with low-float IPOs, we often see press releases and other announcements dropped going into, or slightly following LPX, presumably as insiders attempt to drive up the share price before they are able to exercise their warrants and sell their shares.

+++

Here are the LPX setups I’m watching to potentially patiently build positions.Most of these are previous Chinese Stealth IPOs sitting at relatively low prices. The risk here is that they are duds and don’t make any kind of run into LPX. Those at the $2.00 mark can relatively easily drop down to the $0.80 level, but we’ve also seen them run as high as $20+ (HUDI SOPA). The bigger risk is that they simply take too long to pan out and you end up watching them bleed out – once we get about 2 weeks past the LPX, you gotta manage your downside with stop-losses: ideally above entry, which is why I start patiently bottom-feeding on these a few weeks ahead of LPX.
We also see these sometimes take much longer than expected; see BEAT, which finally ran this past week or so: there were a lot of long-term bag-holders in that one that finally got an out – and holding past the initial pop-day is not as easy as it sounds.

Another approach is to simply be aware of these as potential LPX movers, and if you see one of them pop up on a pre-market scanner, check to see if there’s a news headline: even a fluffy PR drop can get these moving pretty hard.

To view this content, please subscribe to a Premium Membership.

Recent Posts

Continue reading

IPO Trading Review for the Week of September 26, 2022 – September 30, 2022

IPO Trading Review for the Week of September 26, 2022 – September 30, 2022

October 2, 2022

After a somewhat shorter-than-expected hiatus from the regular stream of low-float IPOs that had been debuting since mid-July, the regulators (namely NASDAQ), opened the door for a test-run under deep scrutiny. The results were just short of disastrous, and make the case for at least some element of shenanigans on the part of underwriters to help deliver some level of demand that outstrips supply in these setups.

And in another more obscure corner of the world of IPO debuts, we saw a Regulation A filing that showed us what kind of craziness can ensue when a company forgoes the traditional underwritten process of going public, with an IPO that could potentially lay the blueprint for Stealth IPOs to follow now that NASDAQ has seemingly cracked down on all Chinese (and foreign, for that matter), IPOs.

So now we’ve seen that the indiscriminate hype surrounding the debut of all comers to the low-float IPO scene has essentially disappeared, and the great likelihood that high levels of scrutiny will sequester high flying Chinese IPO, there are a number of short terms imprecations this has on trading strategies both for allocation requests and debut trades. I’ll go into this more deeply in this week’s weekly preview newsletter, but suffice to say, we’ve reached a point in this cycle of IPO hype/hysteria where we need to reconsider the “gimme-all-I-can-get” allocation request.

+++

Ok, Let’s take a look at what happened last week in IPO Land:

Atlis Motors (AMV) – September 27, 2022 | 1.85M Shares
IPO Price: 27.50
Debut Price: $30.11
Day 1 High: $300.00
Day 1 Low: $30.11
High Since Debut: $300.00
Low Since Debut: $19.81

Day 1 Action: As a Regulation A filing, this one slipped under the radars of most IPO tracking calendars, but the IPO Warriors community was on top of sussing this one out on the morning of the IPO, and was fully aware of the circumstances surrounding this comically disorganized debt. A quick explanation on what a Reg A filing is might be in order, as we haven’t seen one of these since Knightscape (KSCP) debuted on January 27, 2022, but one consistent factor to these has been high volatility following their debuts. A Reg A filing is an IPO where companies bypass the traditional process of employing an underwriter to sell IPO shares into the market to facilitate the initial public offering, instead, the company directly markets their offering to the public.
In the case of AMV, apparently Reg A investors were unable to access their shares on the day of the IPO, so there were no shares available to trade. According to Twitter accounts who claimed to have purchased IPO shares, AST Financial required shareholders to verify their tax ID numbers before transferring allocations to traders’ accounts.
Anyway, the result was a long delay in opening the stock for trading, and unfortunately, by the time they came up with any shares to float, I had gone out for the day. However, the IPO Warriors Premium community was covering this trade in real-time, and at least a few members were able to procure shares on the debut and early halts (though reports were that even some open limit orders failed to fill at buy orders above market price).
The price action was as expected, a debut at $30.11 and insta-halts for the remainder of the day, with the real action coming in after-hours, as the stock was finally released from volatility halts, with an open at $82.12 that then embarked on a massive upside run that culminated at $300.00 before pulling back to the $200 range.

Day 2 Action: The insanity continued in Day 2 pre-market with an opening rally that touched the $300.00 mark before pulling back down to the $150s, and then rallying again back up to $300.00 twice before market open.
Once regular halts came back into play, the share price went into an elevator drop from an opening price of $247.17 to a bottom of $54.11, with several insta-halts down in the process. The stock would hit a bottom of $45.00 at around 1:20 PM EST, but would then rally back up to touch $105.00 in the early minutes of after-hours trading. But that appeared to have marked the end for any upside move.

Looking Ahead: To view this content, please subscribe to a Premium Membership.

+++

Laser Photonics (LASE) – September 30, 2022 | 3M Shares
IPO Price: $5.00
Debut Price: $5.00
Day 1 High: $5.50
Day 1 Low: $2.50
High Since Debut: $5.50
Low Since Debut: $2.50

Day 1 Action: The LASE debut officially marked the end of the recent string of hype and hysteria that had ensured that nearly every low-float IPO that came to market was free money for allocation recipients. Before this one, the only failed IPOs were three deals with warrants involved, and of those, two of them had been scheduled on a crowded day in which two other IPOs out-shined them.
LASE came to market under intense scrutiny, in frigid market conditions, but otherwise had structured a deal that was designed with all the ingredients that we would have expected to deliver some kind of upside pop in normal market conditions. But at the end of the day, there simply wasn’t enough demand to outstrip supply for an upside move. Had the underwriter not stepped in to rescue the debut price with heavy use of the “shoe”, this one could have spelled disaster for all IPO allocation recipients.
In the IPO Warriors Live stream and Premium Discord channel, we managed to suss out the weakness of the debut in the early pre-debut indication period, where early price indications showed a heavy sell-side imbalance on price points in the mid $2 range: an absolute disaster of a debut in the making. Fortunately for most of us, as many traders had put in for large allocations that were ‘generously’ filled, the debut indication jumped in the final minute before the debut up to a break-even price of $5.00, allowing us to set limit orders that vacated our positions at or above our cost basis for a non-loss, or in some cases, a slight win.

Those who failed to recognize the ‘broken’ setup, saw their shares top out at $5.50 (1 cent below an upward halt), before dropping downward into a halt at $4.50, from where it then opened for trading down at $4.00, heading as low as $3.56 before making a climb back up to VWAP at $4.38 before failing to rally again for the remainder of the day, slowly bleeding out to hit a low of $2.56 minutes before the bell. No meaningful after hours rally would materialize.

What is “the shoe”?
This term is perhaps unfamiliar to many newer IPO traders, and is worth understanding: essentially, underwriters typically have an option to purchase up to 15% of additional shares of the stock prior to the closing of the IPO, which it generally within a few days of the stock commencing trading on the selected exchange. So in this case, Alexander Capital had an option to purchase up to 450,000 additional shares at the IPO price. It appears that they chose to purchase roughly 200k shares in the moments right before the IPO debuted, to rescue the share price and give investors an opportunity to get out of their positions without incurring a significant initial loss.
The simple reason for doing this, is that it will keep the underwriter’s clients happy, liquid, and willing to purchase shares in future offerings presented to them by these underwriters.

Day 2 Action: We’ll see if we get a Day 2 rebound rally on Monday.

Looking Ahead: To view this content, please subscribe to a Premium Membership.

+++

Looking forward to future IPOs next week:

To view this content, please subscribe to a Premium Membership.

Recent Posts

Continue reading

IPO Warriors IPO and LPX Preview for September 26 – September 30, 2022

IPO Warriors IPO and LPX Preview for September 26 – September 30, 2022

September 29, 2022

I decided to delay sending out this week’s newsletter until there was something definitive to report regarding the IPO debut calendar. As most of you know, there has been a bit of a moratorium placed on fresh IPO debuts by NASDAQ as they attempt to sort out the root cause of the extreme pop-and-drop movements we’ve been seeing in recent IPOs, particularly the Chinese variety of F-1 filings that have made relatively ridiculous runs from single to triple, even quadruple digits in single trading sessions. The aim appears to be implementing new rules to curb this kind of volatility, or possibly to ensure that shareholders are not trading shares back and forth between their own accounts to either manipulate prices or launder money.

Meanwhile, a rather obscure IPO (AMV) managed to squeak through the cracks on Tuesday under Regulation A and Regulation CF crowdfunding offerings (so, no underwriters and no recent S-1 filing). We were on top of it and covering the debut in the Premium Discord channel: a few of us hopped in on the debut and caught a monster run from an opening trade of $30 that ripped as high as $300.00 in after hours trading (I was already out for the day when it finally debuted). This one didn’t appear to be any kind of Stealth setup – simply a case of mishandled processing where the majority of shareholders were unable to sell their IPO shares on the debut: so basically a massive logistical oversight by the company, while NASDAQ appears to have been more focused on scrutinizing Chinese debuts. Oh well, clearly the IPO process is not as orderly as we might expect it to be, and not the first time an IPO has been mishandled on its debut (remember GCT? Wasn’t even supported for trading on WeBull after having handed out allocations through WeBull’s IPO Center requests!).

On the bright side, it appears that we DO have at least one confirmed, standard IPO this week, and I’m excited to review it.

+++

This Week’s IPOs:

  • Laser Photonics (LASE) – September 30, 2022 | 3M Shares

+++

Ok, Let’s jump in:

To view this content, please subscribe to a Premium Membership.

+++

Recent Posts

Continue reading

Play a Song - Save a Dog

Saving Dogs Costs NOTHING!    Just play music from TheSound.com and royalties go towards dog rescue.